Filtered By:
Infectious Disease: Hepatitis C
Therapy: Stem Cell Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 63 results found since Jan 2013.

Hepatitis C detector promises hope and nothing more | Síle Lane
Wherever people are confronted with serious threats and a lack of solutions there is a potential market in false hopeA new device that supposedly detects diseases remotely is being promoted. According to an excited report earlier this week in the Guardian, about a demonstration of the device in an Egyptian hospital, its developers hope it will first be used to detect swine flu and hepatitis C, and later other diseases.What is being plugged here is hope and nothing more. The device looks like a car radio aerial attached to a handle. It is said to work by detecting a specific frequency emitted by infected liver cells. It is ...
Source: Guardian Unlimited Science - February 28, 2013 Category: Science Tags: Blogposts Controversies Infectious diseases Health guardian.co.uk Medical research Society Science and scepticism Source Type: news

'Friendly' virus repairs damaged liver cells (but only in mice)
Conclusion This study showed it was possible to engineer and inject instructions that transform myofibroblasts into liver cells in mice with liver disease, which is quite a feat. Not all delivery mechanisms, called vectors, worked, but in those that did, the new liver cells looked normal, replaced some of the dying cells, and led to less damage due to collagen build up. Despite the alcoholism-related headline, the mice did not have alcohol-induced liver damage – although this is a major cause of liver damage in people. This study serves to prove this approach is feasible, and was successful in doing this. Researchers wi...
Source: NHS News Feed - June 3, 2016 Category: Consumer Health News Tags: Genetics/stem cells Lifestyle/exercise Medical practice Source Type: news

U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously rec...
Source: Johnson and Johnson - March 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Hepatic Natural Killer Cells: Organ-Specific Sentinels of Liver Immune Homeostasis and Physiopathology
Joanna Mikulak1,2, Elena Bruni1,2, Ferdinando Oriolo1,2, Clara Di Vito1 and Domenico Mavilio1,2* 1Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Milan, Italy 2Department of Medical Biotechnologies and Translational Medicine, University of Milan, Milan, Italy The liver is considered a preferential tissue for NK cells residency. In humans, almost 50% of all intrahepatic lymphocytes are NK cells that are strongly imprinted in a liver-specific manner and show a broad spectrum of cellular heterogeneity. Hepatic NK (he-NK) cells play key roles in tuning liver immune response in b...
Source: Frontiers in Immunology - April 29, 2019 Category: Allergy & Immunology Source Type: research

SOGC Guideline Retirement Notice No. 2
Conclusion [J Obstet Gynaecol Can 35 (2013) S42-S43] Chapter 10 Case Studies [J Obstet Gynaecol Can 35 (2013) S44-S47] Appendix 1. Apology for the Forced Relocation of Inukjuak and Pond Inlet Families [J Obstet Gynaecol Can 35 (2013) S48] Appendix 2. Apology for the Residential School System [J Obstet Gynaecol Can 35 (2013) S49] Appendix 3. Avoiding Re-Traumatization of Sexual Abuse/Assault Victims During the Birthing Process [J Obstet Gynaecol Can 35 (2013) S50].PMID:36241341 | DOI:10.1016/j.jogc.2022.08.012
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - October 14, 2022 Category: OBGYN Source Type: research

Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
CONCLUSIONS: The prevalence of renal adverse events after treatment with cisplatin, carboplatin, ifosfamide, radiation therapy involving the kidney region and/or nephrectomy ranged from 0% to 84%. With currently available evidence, it was not possible to draw any conclusions with regard to prevalence of and risk factors for renal adverse effects. Future studies should focus on adequate study design and reporting and should deploy multivariate risk factor analysis to correct for possible confounding. Until more evidence becomes available, CCS should be enrolled into long-term follow-up programmes to monitor their renal func...
Source: Cochrane Database of Systematic Reviews - October 8, 2013 Category: Journals (General) Authors: Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY, Bökenkamp A, Blufpand H, van Dulmen-den Broeder E, Veening MA, Kremer LC, Jaspers MW Tags: Cochrane Database Syst Rev Source Type: research

Stem cells as an ideal carrier for gene therapy: A new approach to the treatment of hepatitis C virus
CONCLUSION: Gene therapy, either directly and in vivo or indirectly and in vitro, requires carriers (vectors) to transfer the gene. These carriers are divided into two groups, viral and non-viral. In indirect gene therapy, living cells are isolated from a person's body and genetically modified. Stem cells have the properties to transfer the desired genes to the patient's body, including the ability to proliferate for a long time and differentiate into the tissue cells in which they are located.PMID:36150664 | DOI:10.1016/j.trim.2022.101721
Source: Transplant Immunology - September 23, 2022 Category: Transplant Surgery Authors: Alireza Rafati Hadi Esmaeili Gouvarchin Ghaleh Afsaneh Azarabadi Mahmood Reza Masoudi Elmira Afrasiab Akbar Ghorbani Alvanegh Source Type: research

A Multidisciplinary Team Approach to the Treatment of Liver Cirrhosis
CONCLUSION: An MDT can improve the efficacy and prognosis of patients with cirrhosis and improve patient compliance. After multi-disciplinary intervention, the mortality spectrum of long-term survival patients with cirrhosis changes, and the mortality rate of liver cancer and non-liver disease increases.PMID:34712056 | PMC:PMC8548059 | DOI:10.2147/JIR.S328334
Source: Cell Research - October 29, 2021 Category: Cytology Authors: Yue-Rong Zhang Hui Wang Ning Zhou Yao-Di Zhang Yan Lin Li-Yang Wu Shi-Fang Wei Yan-Yun Ma Chun-Xia Wang Source Type: research

Controversial Oxygen Therapy ZAPS Cancer
Get more oxygen into your blood, and it instantly destroys infections, bacteria, fungi, and viruses. Oxygen can even destroy cancer cells without harming healthy cells. In today’s world, getting oxygen to your cells is not as easy as it used to be. Even simple nutritional deficiencies like a lack of omega-3s can prevent oxygen from reaching your cells. When my new wellness center opens in October, I’m introducing several new oxygen therapies including an overlooked yet powerful technology called ozone therapy. But ozone is controversial. It attracts attention from the Feds because it WORKS. And anything that ki...
Source: Al Sears, MD Natural Remedies - July 28, 2015 Category: Complementary Medicine Authors: Dr. Al Sears Tags: Anti-Aging Source Type: news

Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news